510 related articles for article (PubMed ID: 25486958)
21. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
22. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
[No Abstract] [Full Text] [Related]
23. Relapsed childhood acute lymphoblastic leukaemia.
Bhojwani D; Pui CH
Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
[TBL] [Abstract][Full Text] [Related]
24. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
25. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y; Yang Y; Hong R; Zhao H; Wei G; Wu W; Xu H; Cui J; Zhang Y; Chang AH; Hu Y; Huang H
Blood Cancer J; 2020 Oct; 10(10):105. PubMed ID: 33077713
[No Abstract] [Full Text] [Related]
26. Pediatric Acute Lymphoblastic Leukemia.
Rheingold SR
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
[No Abstract] [Full Text] [Related]
27. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
Viardot A; Sala E
Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
[TBL] [Abstract][Full Text] [Related]
28. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
30. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Aminov S; Giricz O; Melnekoff DT; Sica RA; Polishchuk V; Papazoglu C; Yates B; Wang HW; Sahu S; Wang Y; Gordon-Mitchell S; Leshchenko VV; Schinke C; Pradhan K; Aluri S; Sohn M; Barta SK; Agarwal B; Goldfinger M; Mantzaris I; Shastri A; Matsui W; Steidl U; Brody JD; Shah NN; Parekh S; Verma A
J Clin Invest; 2024 Feb; 134(8):. PubMed ID: 38376944
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
33. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
Le Jeune C; Thomas X
Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
[TBL] [Abstract][Full Text] [Related]
34. Chemoimmunotherapy in acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N
Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
[TBL] [Abstract][Full Text] [Related]
35. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
36. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
[TBL] [Abstract][Full Text] [Related]
37. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
Chen R; Song XT; Chen B
Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
[TBL] [Abstract][Full Text] [Related]
38. Novel Therapies in Acute Lymphoblastic Leukemia.
Phelan KW; Advani AS
Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
[TBL] [Abstract][Full Text] [Related]
39. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD22 CAR Therapy Leads to ALL Remissions.
Cancer Discov; 2017 Feb; 7(2):120. PubMed ID: 28069570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
